Raising the Bar in Atopic Dermatitis: Unpacking the practice-changing implications of the LEVEL UP study in AD

Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the health-check domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /dom76025/wp-includes/functions.php on line 6121
Raising the Bar in Atopic Dermatitis: Unpacking the practice-changing implications of the LEVEL UP study in AD - The Dermatology Digest

About This Educational Video Series

This educational video series provides expert commentary on the results and implications of Level Up, the first head-to-head trial in atopic dermatitis assessing upadacitinib (Rinvoq, AbbVie) at a starting dose of 15mg daily vs. dupilumab (Dupixent, Sanofi and Regeneron Pharmaceuticals) at its labeled dose.